EMA’s CHMP Issues Positive Opinion for Roche’s Tecentriq SC Subcutaneous Formulation
The Committee for Medicinal Products for Human Use (CHMP) under the European Medicines Agency (EMA)...
PD-1/L1
AstraZeneca’s Imfinzi Gains NMPA Approval for First-Line Cholangiocarcinoma Treatment
The National Medical Products Administration (NMPA) of China has indicated on its website that it...
BeiGene Ltd Reports Q3 2023 Financial Results with 102% YOY Revenue Increase
BeiGene Ltd (NASDAQ: BGNE; HKG: 6160; SHA: 688235) has released its financial results for the...
ImmVira’s MVR-T3011 IV Achieves Positive Outcomes in US Phase I Clinical Study
Shenzhen-based biotechnology company ImmVira has announced the successful completion of Phase I clinical studies in...
Gilead Sciences and Arcus Biosciences Announce Positive Phase II Data for Domvanalimab Combination Therapy
Gilead Sciences (NASDAQ: GILD) and Arcus Biosciences (NYSE: RCUS) have this week released preliminary data...
BioNTech Secures Exclusive Rights to Biotheus Inc.’s BsAb PM8002 in Landmark Deal
Germany’s BioNTech (NASDAQ: BNTX) has entered into an exclusive license and collaboration agreement with China-based...
Seagen’s Adcetris Combo with Keytruda Shows Promising Results in Phase II Study
Seagen (NASDAQ: SGEN), currently in the process of being acquired by Pfizer (NYSE: PFE), has...
Amoy Diagnostics Receives NMPA Approval for MSI Detection Kit as Companion Diagnostic for Immunotherapy
Amoy Diagnostics Co., Ltd (AmoyDx, SHE: 300685), a prominent player in the Chinese diagnostics industry,...
Eli Lilly & Co. Reports 36% YOY Sales Growth in Q3 2023 with Key Drug Performances
Eli Lilly & Co., (NYSE: LLY) has announced its financial results for the third quarter...
3SBio Inc. and CStone Pharmaceuticals Enter Strategic Partnership for Nofazinlimab
China-based 3SBio Inc., (HKG: 1530) has announced a strategic partnership and exclusive licensing agreement with...
Shanghai Henlius Biotech’s HanSiZhuang Shows Positive Results in Phase III ASTRUM-002 Study
Shanghai Henlius Biotech Inc., (HKG: 2696), a leading biopharmaceutical company in China, has unveiled positive...
Coherus’s Loqtorzi Gains FDA Approval for Nasopharyngeal Carcinoma Treatment
Coherus Biosciences (NASDAQ: CHRS) executives held an investor conference call on October 30, 2023, to...
Boan Biotech Enrolls First Patient in Phase III Study for Opdivo Biosimilar BA1104 in China
Boan Biotech (HKG: 6955), a biopharmaceutical company based in China, has announced the enrollment of...
CStone Pharmaceuticals Receives NMPA Approval for Sugemalimab in R/R ENKTL
CStone Pharmaceuticals (HKG: 2616), a China-based biopharmaceutical company, has announced that it has received a...
Alphamab Oncology and 3D Medicines Gain FDA Approval for Envafolimab Phase III Trial
Partners Alphamab Oncology (HKG: 9966) and 3D Medicines (HKG: 1244) have announced that they have...
Fosun Pharma Gains NMPA Approval for Clinical Trials of HLX42 and HLX43 ADCs
Shanghai Fosun Pharmaceutical (Group) Co., Ltd (SHA: 600196) has announced that it has received approval...
Junshi Biosciences’ PD-1 Inhibitor Loqtorzi Approved by FDA for Nasopharyngeal Carcinoma
China-based Shanghai Junshi Biosciences Co., Ltd (HKG: 1877; SHA: 688180) has announced that the US...
Shanghai Henlius Biotech and Intas Pharmaceuticals Ink New Licensing Deal for PD-1 mAb
China’s Shanghai Henlius Biotech Inc., (HKG: 2696) has announced a new licensing agreement with India-based...
BMS Revenue Slips Due to Revlimid Erosion: Q3 2023 Insights
Bristol Myers Squibb (BMS; NYSE: BMY) reported a 3% year-on-year (YOY) revenue decline, excluding foreign...
Shanghai Henlius Initiates Global Phase III Study for HanSiZhuang in LS-SCLC
China’s Shanghai Henlius Biotech, Inc. (HKG: 2696) has announced the milestone of the first patient...